Clinical trial · no report yet · Phase 2
iMMagine-1
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
- NCT05396885 ↗
- Active not recruiting
- Kite, A Gilead Company
- 51 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 23 | |
| X threads | 16 | |
| Podcasts | 12 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Study of CART-ddBCMA for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- anitocabtagene-autoleucel
- Arms
- anitocabtagene-autoleucel · Experimental
- Enrollment
- 136
- Primary outcomes
- Overall Response Rate (ORR)
- Sponsor
- Kite, A Gilead Company with Arcellx, Inc.
- Start
- Jul 15, 2022
- Primary completion
- Dec 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05396885 · updated Feb 11, 2026